دورية أكاديمية
أعرض في EDS

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
المؤلفون: Ogdie, AlexisAff1, IDs41927024003867_cor1, Merola, Joseph F., Mease, Philip J., Ritchlin, Christopher T., Scher, Jose U., Lafferty, Kimberly Parnell, Chan, Daphne, Chakravarty, Soumya D.Aff6, Aff7, Langholff, Wayne, Wang, Yanli, Choi, Olivia, Krol, Yevgeniy, Gottlieb, Alice B.
المصدر: BMC Rheumatology. 8(1)
قاعدة البيانات: Springer Nature Journals
الوصف
تدمد:25201026
DOI:10.1186/s41927-024-00386-7